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Original Article
Clinical Outcomes of Sirolimus with Eluting Stent Implantation in Coronary
Artery Disease
Munsif Ali1, Syed Mumtaz Ali Shah2, Zaman Shah3, Islam Hussain4, Khezar Shahzada Syed5, Hadi Mohammad Khan6
The Aga Khan University Hospital, Karachi1,3,4,5,6, Department of Cardiology2, Shifa International Hospital, Islamabad, Pakistan. 
Abstract
Objective: To evaluate the immediate post procedure, thirty-days, and six-months clinical outcomes of sirolimus-
eluting stents (SES) implantation in patients with single and multivessel coronary artery disease (CAD). 
Methods: A case series of all consecutive patients undergoing percutaneous coronary interventions (PCI) with
SES implantation at Shifa International Hospital, Islamabad,  were evaluated at early post-procedure, 30-days
and six-months clinical follow-up for the incidence of major adverse cardiac event (MACE). This included death,
nonfatal myocardial infarction (MI) and repeat revascularization.
Results: Out of 206 consecutive patients, 324 had SES implanted. Cumulative MACE rate was 2.93% and 6%
at 30-days and six-months follow-ups respectively. Five patients developed ST-segment elevation MI (STEMI).
One patient developed non-STEMI. Emergency Coronary Artery Bypass Grafting (CABG) was done in two
patients. Repeat (PCI) was carried in three (1.46%) patients for acute in-stent thrombosis. Diabetes Mellitus and
multivessel stenting were found to be the independent predictors for acute in-stent thrombosis (P-value <0.02
and 0.05 respectively).
Conclusion: SES implantation in coronary artery disease can be safe and effective MACE at one and six
months follow-ups (JPMA 58:449;2008).
Introduction
Drug-eluting stents have been a major advance in
percutaneous coronary revascularization. Widespread use of
these stents has been spurred by substantial reductions in
restenosis rates when compared with bare metal stents.1-3
Although the use of stents has reduced the rate of
restenosis as compared to balloon angioplasties, the rate of
in-stent restenosis (ISR) still continues to be between 15-
30%.1 Randomized trials such as RAVEL and SIRIUS have
shown the efficacy of SES over bare metal stents to reduce
angiographic restenosis and repeat revascularizations, in
selective patients with relatively simple lesions.4,5 In
reported randomized studies, treatment of stenotic lesions in
native coronary arteries by the implantation of the SES or
paclitaxel-eluting stent, showed a low percentage of
angiographic restenosis and additional revascularization.6
To the best of our knowledge we could not find any
study that has evaluated the safety and effectiveness of SES
implantation in coronary artery diseases in Pakistan. In this
study, early and mid-term clinical outcome of SES
implantation in CAD patients in our country was evaluated. 
Patietns and Methods
It   was a case series of all consecutive patients from
April 2002 till February 2005, who underwent PCI with
SES at Shifa International Hospital, Islamabad. Patients
medical records were reviewed for the intra and immediate
post-procedure events, in-hospital, one-month and six-
months post-procedure outcomes. 
All procedures were performed according to
standard intervention techniques. All patients were started
on aspirin 300 mg and clopidogrel 300 mg bolus at least
four hours prior to the procedure. During the procedure
intravenous heparin (70 micrograms/kg) was given to
achieve an activated clotting time of at least 250 seconds.
Glycoprotein IIb/IIIa inhibitors  (eptifibatide, abciximab,
and tirofiban) were administered at the discretion of the
operator. Baseline clinical, procedural information and in-
hospital complications were recorded. Patient cohort
included all the patients who had stable angina (exercise
tolerance test [ETT] or thallium scan suggestive of
myocardial ischaemia) and acute coronary syndrome
(ACS). Procedures performed within first 24 hours of an
acute MI were classified as rescue or primary angioplasty,
regardless of any preceding failed thrombolysis. Patients
treated after 24 hours of an acute episode of MI were
classified as post MI unstable angina (Braunwald
classification C). Stent implantation was performed with
lesion predilatation or direct stenting according to the
evaluation of the operator. MACE was defined as
occurrence of 1) death, 2) non fatal MI, and 3) repeat
revascularization of the target lesion. Definite diagnosis of
an MI required a significant rise in plasma levels of cardiac
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enzymes (troponins I or creatinine kinase MB) together
with ischaemic symptoms or dynamic electrocardiographic
(ECG) changes. Post procedure cardiac enzymes were not
done routinely. They were only done in patients who either
had symptoms or dynamic ECG changes suggestive of an
acute cardiac event. Target lesion revascularization (TLR)
was defined as any surgical or percutaneous re-intervention
done as a result of significant luminal narrowing within the
stent or 5mm distal or proximal peri-stent segment.3,6 Target
vessel revascularization (TVR) was defined as any re-
intervention driven by lesions located in treated vessel
beyond the target lesion limits.3,6 Angiographic success of
angioplasty procedure was defined as restoration of TIMI
flow grade 3 and less than 30% in-lesion stenosis after stent
placement.2,5 In the study protocol, stent thrombosis was
defined as acute if it occurred within 24 hours after an index
procedure, subacute if it occurred between 1 and 30 days
after the procedure, and late if it occurred more than 30 days
after the procedure. Acute and subacute stent thrombosis
was classified on the basis of vessel occlusion on
angiography, any recurrent Q-wave MI in an area irrigated
by the stented vessel, or death from cardiac causes. Late
stent thrombosis was diagnosed on the basis of any
recurrent MI with vessel occlusion on angiography.7
Results were presented as frequencies, percentages
or mean with standard deviation (SD). For comparison
between groups with categorical data, chi square test was
used. P-values of less than 0.05 were considered statistical
significant. Cox regression analysis was used to identify
independent predictors of MACE. Data was entered and
analyzed using SPSS version 13.
Results
A total of 282 lesions were treated with 324 SES
implantations in 206 patients (79% males and 21% females)
with the mean of 1.37±0.64 lesions per patient, median and
mode of 2. Mean age at presentation was 56.03 ± 10.17
years. Forty two percent of the patients were hypertensive,
37% were smokers and 35% diabetics. Hundred and seven
(60%) patients had unstable angina, 4 (2%) had STEMI and
30 (14.6%) had an NSTEMI.  Hundred and eight (52%)
patients had single vessel disease, 67 (33%) had two-vessel
disease while the remaining 31 (15%) patients had three-
vessel disease. Maximum number of lesions were located in
left anterior descending artery 134(47.5%). Most lesions
stented were either located proximally (49.6%) or in mid
segment of the vessels (31.2%). Fifty-five (19.5%) lesions
were located in small vessels of less than 2.5mm in diameter.
More than half (53.2%) of the lesions were directly stented.
Overlap stenting was done in 27.7 % of the lesions and
maximum stented length was 79 mm. Bifurcation stenting
was done in 5.7% of the lesions. Post stent dilatation was
done in 3.5% of the lesions. In 0.71% same delivery balloon
was used and in 2.84% of lesions different delivery balloon
was used. In all the cases post stent dilatation was done for
stent under expansion (Table 1).  
All patients received aspirin and clopidogrel at least
four hours prior to the procedure. Glycoprotein IIb/IIIa
Table 1. Procedural characteristics of the patients.
Procedural findings Frequency Percent
Target Vessel 
LAD
Lcx
RCA
LIMA-anastomosis
CABG
Location in Vessel 
Ostial   
Proximal
Mid
Distal
Bifurcation
De novo lesions
In-stent restenosis
Lesion thrombosis
Total occlusions
> 3 months
< 3 months 
Direct Stenting
Balloon dilatation (prior to stenting)
Post Stent Dilatation
Same delivery Balloon
Different delivery balloon
Overlap stenting
134
43
100
4
1
36
140
88
18
16
273
9
21
2
3
150
132
10
2
8
92
47.5
15.2
35.5
1.4
0.4
12.8
49.6
31.2
6.4
5.7
96.8
3.2
7.4
0.7
1.1
53.2
46.8
3.5
0.7
2.84
27.7
Key: LAD: Left anterior descending, Lcx: Left circumflex, RCA: Right coronary artery, 
LIMA: Left internal mammary artery, CABG: Coronary artery bypass graft
Table 2. In-hospital and 30 days incidence of major adverse cardiac
events.
Events
In-Hospital
Mace
(frequency and
percent)
30 Days Mace
(frequency and
percent)
Composite 30
Days Mace
(frequency and
percent)
Death
Nstemi
Stemi
Total mace
Repeat PCI
Emergent cabg
1 (0.49%)
0
3 (1.46%)
4 (1.94%)
3 (1.46%)
0
0
1 (0.49%)
1 (0.49%)
2 (0.98%)
0
2 (0.98%)
1 (0.49%)
1 (0.49%)
4 (1.95%)
6 (2.93%)
3 (1.46%)
2 (0.98%)
Key: MACE: Major adverse cardiac events, NSTEMI: Non ST-segment elevation myocardial
infarction, STEMI: ST-segment elevation myocardial infarction, PCI: Percutaneous coronary
intervention, CABG: Coronary artery bypass graft
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inhibitor was given to 42.8% of the patients intra and post
procedurally, out of which 13% were diabetics. Beta-
blockers were prescribed to 182 (88.3%) patients. In 22
(11%) patients beta-blockers were withheld due to asthma
and low blood pressure at the time of discharge. Statins
were prescribed to 202 (98.1%) patients on discharge.
Angiotensin converting enzyme inhibitors (ACE-I) were
given to 188 (91.3%) patients on discharge. In 10 (5%)
patients ACE-I were changed to angiotensin receptor
blocking agents (ARBs) at 1-month follow up because of
intractable cough associated with the ACE-I.
As stated in Table 2, one patient went into
ventricular fibrillation and had sudden cardiac arrest during
the procedure. About 1-hour post procedure, 2 patients
developed severe chest pain and dynamic ECG changes.
Re-angiography showed acute periprocedure instent
thrombosis. After restenting and adjunctive therapy with
glycoprotein 2b3a receptor inhibitor, final TIMI flow grade
3 was restored. One patient developed NSTEMI 8 hours
after the index procedure despite being on glycoprotein
2b3a receptor inhibitor peri and post procedure. Repeat PCI
was done for acute instent thrombosis, glycoprotien 2b3a
receptor inhibitors and low molecular weight heparin in full
therapeutic dose was given till 3 days after the procedure.
All these patients who developed acute in stent thrombosis
were diabetics. At 30 days clinical follow up 2 patients
underwent coronary artery bypass grafting. No patient
developed major haematoma requiring tranfusion,
pseudoaneurysm or need for vascular repair. 
Six months clinical follow-ups of 156 patients were
reviewed out of  206 patients. Table 3 reports the adverse
events at 6 months follow-up. Cumulative MACE incidence
was 9 (6%), with 3 (2%) deaths, 6 (4%) MIs and 6 (4%)
repeat revascularization. One patient had sudden cardiac
arrest three months after the index procedure and died. The
other patient, insulin-dependant type-2 diabetic, presented
with unstable angina 5 months after the procedure. No
independent predictors of MACE, TLR free survival and
TVR free survival were found. Variables included in this
model were ACS, diabetes mellitus and multivessel
stenting. In addition predictors of acute instent thrombosis
were identified. Diabetes mellitus and multivessel stenting
were significantly associated with acute in-stent thrombosis
(P <0.02 and <0.02 respectively). 
Discussion
In-stent restenosis (ISR) remains a challenge for
interventional cardiologists. The exceedingly encouraging
data from randomized trials of drug-eluting stents with
selected simple lesions and an unselected cohort of patients
have shown that SES implantations are related to decrease
incidence of ISR and repeat revascularization.8-10 Previous
data has uncovered that the degree of neointimal
proliferation, manifested as the mean (+/-SD) late luminal
loss, was significantly lower in the sirolimus-stent group
(-0.01+/-0.33 mm) than in the standard-stent group (0.80+/-
0.53 mm, P<0.001). None of the patients in the sirolimus-
stent group, as compared with 26.6% of those in the
standard-stent group, had restenosis of 50% or more of the
luminal diameter (P<0.001).8
In this study, only 3.2% of the patients had ISR as a
complication of SES implantation, which is much lower,
compared to bare metal stents and paclitaxel eluting
stents.10,11 In terms of ISR incidence, our results are
encouraging and comparable to similar major studies
conducted in developed countries.6,12 The low incidence of
ISR with SES implantation can be explained due to its
cytostatic and anti-inflammatory properties. Sirolimous, a
naturally occuring antibiotic, inhibit cell proliferation at the
G-1 phase of the cell cycle, by targeting replicating smooth
muscle cells. It also reduces local inflammatory cell activity
in the vessel wall.13-15
In this study, MACE incidence and repeat
revascularization turned out to be six and four percent
respectively, despite the fact that most patients in the study
had ACS with complex lesions and had very long lesions
(maximum stented length of 79 mm), and direct stenting
had been done in majority of the patients (54.2%). The
figure of MACE incidence in this study was lower
comparable to previous such studies conducted in
developed countries (6% vs 13.8%).3,5,12
In this study, we found that most patients underwent
repeat PCI rather than CABG for TLR and TVR. This is an
important finding since majority of restenosis seen with
SES is focal and can easily be treated with repeat PCI rather
than CABG.6
Table 3. Six-months clinical outcomes.
Event Frequency Percent
Death
NSTEMI
STEMI
Cumulative MACE 
TLR
PCI
CABG
TVR
PCI
CABG
3
1
5
9
5
3
2
1
1
0
2
0.66
3.33
6
3.33
2
1.33
0.67
0.67
0
Key: NSTEMI: Non ST-segment elevation myocardial infarction, STEMI: ST-segment elevation
myocardial infarction, MACE: Major adverse cardiac events, TLR: Target lesion
revascularization, PCI: Percutaneous coronary intervention, CABG: Coronary artery bypass
graft, TVR: Target vessel revascularization 
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Further more, diabetes mellitus and multivessel
stenting are significant independent predictors of acute in-
stent thrombosis. This necessitates a more liberal use of
glycoprotien IIb/IIIa inhibitors in this subset of patients.
However, long-term follow-up is needed to look for the
impact of diabetes on MACE incidence and ISR.
The safety of drug-eluting stents has been called into
question by recent reports of increased stent thrombosis,
myocardial infarction, and death. Stent thrombosis after one
year was more common with both sirolimus-eluting stents
and paclitaxel-eluting stents than with bare-metal stents.15-20
In this study, 156 patients out of 206 were reviewed
for a period of six months. Smaller number of patients and
short follow-ups were our limitations. 
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